Manuscripts (30 of 556)

Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial
Ivan Koychev, Graham Reid, Maggie Nguyen, Robert J. Menz, Dan Joyce, Svati H. Sha, Rury R. Holman
Alzheimers Res Ther. 2024;16:212. Published:02-Oct-2024. PMID:39358806. doi:10.1186/s13195-024-01573-x

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults
Ivan Koychev , Amanda I Adler, Paul Edison, Brian Tom, Joanne E Milton, Joe Butchart, Adam Hampshire, Charles Marshall, Elizabeth Coulthard, Henrik Zetterberg, Peter Hellyer, Francesca Cormack, Benjamin R Underwood, Catherine J Mummery, Rury R Holman
BMJ Open 2024;14:e081401. doi:10.1136/bmjopen-2023-081401

Comparison of Medical Resources and Costs among Patients with Coronary Heart Disease and Impaired Glucose Tolerance in the Acarbose Cardiovascular Evaluation (ACE) Trial
Frauke Becker, Liam Mc Morrow, Jose Leal, Ruth L. Coleman, Hertzel C. Gerstein, Lars Rydén, Stefan Schröder, Alastair M. Gray, Rury R. Holman; for the ACE Study Group
Journal of Diabetes 2023;16:e13473. Published:Feb-2024. Epub:02-Nov-2023. PMID:37915263. doi:10.1111/1753-0407.13473

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
Nat Commun. 2023;14:1025. Published:23-Feb-2023. Epub:23-Feb-2023. PMID:36823106. doi:10.1038/s41467-023-36541-w

Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study
Shishi Xu, Ruth L. Coleman, Qin Wan, Yeqing Gu, Ge Meng, Kun Song, Zumin Shi, Qian Xie, Jaakko Tuomilehto, Rury R. Holman, Kaijun Niu and Nanwei Tong
Cardiovasc Diabetol. 2022;21:182. Published:13-Sep-2022. PMID:36100925. doi:10.1186/s12933-022-01622-5

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial
José Leal, Fraucke Becker, Lee-Ling Lim, Rury R. Holman, Alastair M. Gray
J Diabetes 2022;14:455-464. Published:Jul-2022. PMID:35876124. doi:10.1111/1753-0407.13294

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman and for the EXSCEL Study Group
Cardiovasc Diabetol. 2022;21:116. Published:27-Jun-2022. PMID:35761271. doi:10.1186/s12933-022-01555-z

Predicting the Risk of Developing Type 2 diabetes in Chinese People who have Coronary Heart Disease and Impaired Glucose Tolerance
Shishi Xu, Charles A. B. Scott, Ruth L. Coleman, Jaakko Tuomilehto, Rury R. Holman
Journal of Diabetes 2021;13:817-826. Published:Oct-2021. Epub:04-Mar-2021. PMID:33665904. doi:10.1111/1753-0407.13175

Predicting Heart Failure Events in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial
Malgorzata Wamil, John JV McMurray, Charlie AB Scott, Ruth L Coleman, Yihong Sun, Eberhard Standl, Lars Rydèn, Rury R Holman
Diabetes Res Clin Pract. 2020;170:108488. Published:Dec-2020. Epub:06-Oct-2020. PMID:33035598. doi:10.1016/j.diabres.2020.108488

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial
Hertzel C. Gerstein, Ruth L. Coleman, Charles A.B. Scott, Shishi Xu, Jaakko Tuomilehto, Lars Rydén, Rury R. Holman for the ACE Study Group
Diabetes Care 2020;43:2242-2247. Published:Sep-2020. Epub:08-Jul-2020. PMID:32641379. doi:10.2337/dc19-2046

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)
Schilling W, Callery J, Taylor W, Mukaka M, Ekkapongpisit M, Watson J, Chandna A, Panapipat S, Tubprasert J, Yuentrakul P, Waithira N, Cope T, Dhorda M, Cruz C, von Seidlein L, Milton J, LLewelyn M, Adler A, Chotivanich K, Cheah PY ... [Show all 26] ... White N
Wellcome Open Research 2020;5:20. doi:10.12688/wellcomeopenres.15784.1

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto and Rury R. Holman
Cardiovasc Diabetol 2019;18:135. Published:17-Oct-2019. PMID:31623625. doi:10.1186/s12933-019-0933-y

Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance
Yidong Wei, Wen Xu
Future Cardiology 2019;15:127-133. Published:Mar-2019. Epub:22-Feb-2019. PMID:30793928. doi:10.2217/fca-2018-0062

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, Weifeng Tang, David W. Boulton, Srinivas Bachina, Robert D. Fox, Peter Fenici Marcus Thuresson, Robert J. Mentz, Adrian F. Hernandez, and Rury R. Holman
Diabetes Care 2019;42:318-326. Published:Feb-2019. Epub:06-Dec-2018. PMID:30523029. doi:10.2337/dc18-1871

What does the ACE trial tell us? – Commentary
Rury R. Holman
Journal of Diabetes 2018;10:683-685. Published:Aug-2018. Epub:17-May-2018. PMID:29774661. doi:10.1111/1753-0407.12770

Effect of race on the glycaemic response to sitagliptin. Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Davis TME, Mulder H, Lokhnygina Y, Standl E, Aschner P, Chuang LM, Grado CR, Peterson ED, Holman RR
Diabetes, Obesity and Metabolism 2018;20:1427-1434. Epub:06-Feb-2018. PMID:29405540. doi:10.1111/dom.13242

Baseline Characteristics and Temporal Differences in Acarbose Cardiovascular Evaluation (ACE) Trial Participants
Michael J. Theodorakis, Ruth L. Coleman, Huimei Feng, Juliana Chan, Jean-Louis Chiasson, Junbo Ge, Hertzel C. Gerstein, Yong Huo, Zhihui Lang, John J. McMurray, Lars Rydén, Stefan Schröder, Michal Tendera, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan and Rury R. Holman for the ACE Study Group
Am Heart J 2017;199:170-175. Published:May-2018. Epub:10-Sep-2017. PMID:29754657. doi:10.1016/j.ahj.2017.09.001

Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: A Randomised Controlled Trial
Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan for the ACE Study Group
Lancet Diabetes Endocrinol. 2017;5:877-86. Published:Nov-2017. Epub:13-Sep-2017. PMID:28917545. doi:10.1016/S2213-8587(17)30309-1
[Slides] [Slides #2]
Erratum in :
Lancet Diabetes Endocrinol. 2019;5:PE5, Print:May-2019, Epub:01-May-2019, doi:10.1016/S2213-8587(19)30063-4

Letter regarding AHA Scientific Statement “Drugs That May Cause or Exacerbate Heart Failure.”
Peterson ED, Armstrong PW, Holman RR
AHA website 2017;1. Published:Apr-2017. Epub:27-Apr-2017
[Full text]

Neurokinin B Receptor Antagonism in Women with Polycystic Ovary Syndrome: A Randomized, Placebo- Controlled Trial
Jyothis T George, Rahul Kakkar, Jayne Marshall, Martin L Scott, Richard D Finkelman, Tony W Ho, Johannes Veldhuis, Karolina Skorupskaite, Richard A Anderson, Stuart McIntosh, Lorraine Webber
J Clin Endocrinol Metab 2016;101:4313-4321. Published:Nov-2016. Epub:26-Jul-2016. PMID:27459523. doi:10.1210/jc.2016-1202

Preface – Diabetes prevention and management
Rury R. Holman
Best Pract Res Clin Endocrinol Metab. 2016;30:329. Published:Jun-2016. Epub:16-Jul-2016. PMID:27432068. doi:10.1016/j.beem.2016.07.001

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial [Chinese republication]
Rury R Holman, Mary A Bethel, Juliana CN Chan, Jean-Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel Gerstein, Yong Huo, John J McMurray, Lars Ryden, Winitha Liyanage, Stefan Schröder, Michal Tendera, Michael J Theodorakis, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan for the ACE Study Group
Int J Endocrinol Metab 2016;36:1-4. Published:May-2016. doi:10.3760/cma.j.issn.1673-4157.201.00.00

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial [Chinese Abstract]
Hu Da Yi, Pan Chang Yu, Rury R. Holman.
Chinese Journal of Cardiology 2015;43:412. Published:24-May-2015. doi:10.3760/cma.j.issn.0253-3758.2015.05.008

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Rury R Holman, Mary A Bethel, Juliana CN Chan, Jean-Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel Gerstein, Yong Huo, John J McMurray, Lars Ryden, Winitha Liyanage, Stefan Schröder, Michal Tendera, Michael J Theodorakis, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan for the ACE Study Group
American Heart Journal 2014;168:23-29. Published:Jul-2014. Epub:05-Apr-2014. PMID:24952856. doi:10.1016/j.ahj.2014.03.021

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
Huffman KM, Sun JL, Thomas L, Bales CW, Califf RM, Yates T, Davies MJ, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Haffner SM, Kraus WE.
Metabolism 2014;63:554-561. Published:Apr-2014. Epub:15-Jan-2014. PMID:24559843. doi:10.1016/j.metabol.2014.01.002

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled trial
H.A.W. Neil, U. Ceglarek, J. Thiery, S. Paul, A. Farmer, R. R Holman
Atherosclerosis 2010;213:512-517. Published:Dec-2010. Epub:18-Sep-2010. PMID:21036355. doi:10.1016/j.atherosclerosis.2010.09.013

Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of propectively designed overviews of randomised trials
MacMahon, N Chapman; Blood Pressure Lowering Treatment Trialists' Collaboration
The Lancet 2000;356:1955-1964. Published:09-Dec-2000. PMID:11130523. doi:10.1016/S0140-6736(00)03307-9
[Abstract]

Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycaemia
Peacey SR, Robinson R, Bedford C, Harris ND, MacDonald IA, Holman RR, Heller SR
Diabetes Care 2000;23:1022-1023. Published:Jul-2000. PMID:10895860. doi:10.2337/diacare.23.7.1022

Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade
Hypertension in Diabetes Study Group
Diab Med. 1994;11:773-782. Published:Oct-1994. PMID:7851072. doi:10.1111/j.1464-5491.1994.tb00352.x
[Abstract]

UK Prospective Diabetes Study (UKPDS). IX: Relationships of urinary albumin and N-acetylglucosaminidase to glycaemia and hypertension at diagnosis of type 2 (non-insulin-dependent) diabetes mellitus and after 3 months diet therapy
UKPDS Study Group
Diabetologia 1993;36:835-842. Published:Sep-1993. PMID:8405755. doi:10.1007/BF00400359
[Abstract]